Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06214468
Other study ID # 23-067/2026659-2
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date January 15, 2024
Est. completion date April 30, 2025

Study information

Verified date January 2024
Source University of South Alabama
Contact marie E migaud, PHD
Phone 2514104938
Email mmigaud@southalabama.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Over-the-counter drugs like acetaminophen (e.g., Tylenol®) can be detrimental. In space, astronauts who have pain and constant discomfort use acetaminophen extensively. Investigators are studying the effects of acetaminophen under space-like conditions since acetaminophen might affect astronauts' health. Investigators also wish to see whether a dietary supplement can reduce some negative effects of acetaminophen. It is believed that acetaminophen promotes the productions of chemicals in the body that could be toxic. In this study, measurements of these chemicals in urine after ingestion of 1 tablet of acetaminophen and compare these measurements to when acetaminophen is taken at the same time as a dietary supplement. This study will also explore whether these products are more abundant when blood is placed under conditions that mimic space. Therefore, this study will collect blood from a few volunteers who took acetaminophen, and acetaminophen with the dietary supplement.


Description:

In space, astronauts are constantly exposed to conditions the body is not used to. To relieve pain and discomfort, astronauts often use acetaminophen. This study investigates a possible negative synergistic effect between using acetaminophen and space-like stressors as they both generate oxidative stress and produce toxins that distribute around the body and disrupt cellular function in other tissues. The study seeks to examine whether a dietary supplement, nicotinamide riboside (NR), can reduce some adverse effects of these toxins by reducing their production when taking acetaminophen. The study will measure these materials in urine after ingestion of 1 gram of acetaminophen and compare these measurements to when the same amount of acetaminophen is taken at the same time as NR. It will also evaluate whether these toxins are more abundant when blood is placed under conditions resembling space. Therefore, blood collection from a few volunteers who take acetaminophen, and acetaminophen with NR. Ultimately, this work will establish whether NR could reduce the generation of specific endotoxins. For this study, male and female volunteers are needed to donate urine for testing the effect of 1000mg dose of Tylenol® and one 1000mg dose of Tylenol® with one 250mg dose of Nicotinamide Riboside on the abundance of uremic toxins in urine and in blood. Volunteers are also needed to donate blood.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date April 30, 2025
Est. primary completion date June 15, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - n/a Exclusion Criteria: - Individual allergic to acetaminophen or nicotinamide riboside

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
Acetaminophen and Nicotinamide Riboside
Collection of urine at different time intervals following ingestion of Tylenol plus Nicotinamide Riboside
Drug:
Acetaminophen
Collection of urine at different time intervals following ingestion of Tylenol only

Locations

Country Name City State
United States University of South Alabama Mobile Alabama

Sponsors (5)

Lead Sponsor Collaborator
University of South Alabama National Aeronautics and Space Administration (NASA), Rutgers University, University of Alabama at Birmingham, University of Nevada, Las Vegas

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Count the quantity of NAD(P)(H) present with exposure to acetaminophen, with and without NR Multiple blood draws pre and post dose of acetaminophen plus NR At consent and 6 hours post dose
Primary Count the DNA damage occurring upon space-like stressors following exposure to acetaminophen, with and without NR Multiple blood draws pre and post dose of acetaminophen with or without NR. At consent and 6 hours post dose
Primary Count the quantity of ox-NAD(P) present with exposure to acetaminophen, with and without NR Multiple blood draws pre and post dose of acetaminophen plus NR At consent and 6 hours post dose
Primary Count the quantity of PYR-ribosides present with exposure to acetaminophen, with and without NR A urine sample will be collected from consented volunteers pre and post dose of acetaminophen plus NR Pre-dose and 6 hour, 12 hour and 24 hour post dose following administration and
Primary Count the quantity of PYR-nucleotides present with exposure to acetaminophen, with and without NR A blood sample will be collected from consented volunteers pre and post dose of acetaminophen plus NR Pre-dose and 6 hour, 12 hour and 24 hour post dose following administration and
See also
  Status Clinical Trial Phase
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Active, not recruiting NCT03651778 - GHB Poisoning and Poisoning Induced by Others
Completed NCT04120233 - MW151-101: First-in-human Study of MW151 Phase 1
Recruiting NCT01965275 - High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs Phase 2
Completed NCT01614080 - Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA N/A
Recruiting NCT04659343 - TDM for Optimized Outcome in Patients With mRCC.
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT01135680 - Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100 Phase 1
Completed NCT03947034 - Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
Recruiting NCT03885388 - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma (GTN) Patients With Score of 5-6 Phase 2/Phase 3
Completed NCT00491595 - Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women Phase 1
Recruiting NCT03469063 - Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients N/A
Not yet recruiting NCT04671589 - Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. Phase 4
Completed NCT03280368 - Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
Withdrawn NCT01374061 - Pre Hospital Evaluation of Video Laryngoscopy Phase 4
Completed NCT03994302 - Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
Completed NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Terminated NCT00090844 - Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer Phase 2
Terminated NCT00213642 - Tc-99m Renography and Cisplatin-induced Nephrotoxicity N/A